Covestro AG

Covestro reported Q3 2025 sales of EUR 3.2 billion, down 12% year over year, and EBITDA of EUR 242 million, down 15.7% year over year. Free operating cash flow was positive EUR 111 million in Q3, while 9M free operating cash flow was minus EUR 370 million; net debt increased by EUR 292 million versus end-2024 and the net debt-to-EBITDA ratio was 3.8x. Management narrowed full-year 2025 guidance to EBITDA of EUR 700 million to EUR 800 million, free operating cash flow of minus EUR 400 million to minus EUR 200 million, greenhouse gas emissions of 4.2 million to 4.4 million tonnes, and sales of around EUR 13.0 billion. Capex guidance was maintained at EUR 700 million to EUR 800 million for 2025.

No CEO spoke on the call; CFO Christian Baier led the discussion. Strategically, he emphasized disciplined capital allocation and specialty portfolio expansion, highlighting the Pontacol acquisition and the newly signed Vencorex transaction as value-accretive moves that expand Covestro’s aliphatics footprint in the U.S. and Asia Pacific. His tone was pragmatic but constructive: he repeatedly pointed to active cost actions, progress on the XRG transaction, and confidence in a ramp-up from Dormagen over time.

Baier said Q3 EBITDA of EUR 242 million was supported by short-term contingency savings and long-term structural savings, despite negative pricing, weaker volumes and FX. He noted restructuring costs of EUR 26 million in Q3 and EUR 170 million in the first 9 months, capex of EUR 556 million after 9M, and net debt up by EUR 292 million versus end-2024, with a 3.8x net debt-to-EBITDA ratio. On Dormagen, he estimated an internal insurance benefit of EUR 75 million plus EUR 25 million in deductibles, implying coverage above EUR 100 million for the event, and said the full-year operational burden could reach up to EUR 150 million; he also said no further insurance booking is expected in Q4.

Analysts pressed on the Dormagen outage, asking how much of the estimated EUR 150 million impact is insured and whether the plant would be fully fixed by January 2026; management said ramp-up will continue through 2026 and that insurance coverage should exceed EUR 100 million, but full recovery is not immediate. Questions also focused on weak October pricing and whether the narrowed EBITDA range might need to be lower; Baier said October volatility exists, but current trends still fit the guided EUR 700 million to EUR 800 million range. Another question challenged the status of German FDI approval for the XRG deal, and Baier responded that Covestro is in constructive discussions and remains confident of clearing both German FDI and EU FSR before the December 2 long-stop date.